Biomarkers in fibromyalgia

Current Pain and Headache Reports

Volumn 13, Issue 5, 2009, Pages 343-349

  Ablin, Jacob N ^a   Buskila, Dan ^a   Clauw, Daniel J ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; BIOLOGICAL MARKER; BRAIN DERIVED NEUROTROPHIC FACTOR; CATECHOL METHYLTRANSFERASE; DOPAMINE 4 RECEPTOR; ENKEPHALIN; GLUTAMIC ACID; INTERLEUKIN 8; NERVE GROWTH FACTOR; NORADRENALIN; SEROTONIN 2A RECEPTOR; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN TRANSPORTER; SEX HORMONE; SUBSTANCE P;

ACUPUNCTURE; CLINICAL TRIAL; COLD STRESS; DIFFUSE NOXIOUS INHIBITORY CONTROL; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE MARKER; DISTRESS SYNDROME; ELECTROSTIMULATION; EVENT RELATED POTENTIAL; FAMILIAL DISEASE; FIBROMYALGIA; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GENETIC PREDISPOSITION; HEART RATE VARIABILITY; HEAT STRESS; HUMAN; HYPOTHALAMUS HYPOPHYSIS SYSTEM; IMMUNOREACTIVITY; MUSCLE DISEASE; NEUROIMAGING; NOCICEPTION; NONHUMAN; PAIN ASSESSMENT; PAIN THRESHOLD; POSITRON EMISSION TOMOGRAPHY; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTON NUCLEAR MAGNETIC RESONANCE; REVIEW; SEROTONINERGIC SYSTEM; SINGLE NUCLEOTIDE POLYMORPHISM; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SKIN DISEASE; SLEEP DISORDER; TREATMENT RESPONSE;

BIOLOGICAL MARKERS; FIBROMYALGIA; GENETIC MARKERS; HUMANS; PAIN MEASUREMENT;

EID: 70349633267     PISSN: 15313433     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11916-009-0056-3     Document Type: Review

References (47)

1. Arnold LM, Hudson JI, Hess EV, et al.: Family study of fibromyalgia. Arthritis Rheum 2004, 50:944-952.
2. Buskila D, Neumann L, Hazanov I, Carmi R: Familial aggregation in the fibromyalgia syndrome. Semin Arthritis Rheum 1996, 26:605-611.
3. Kato K, Sullivan PF, Evengard B, Pedersen NL: Chronic widespread pain and its comorbidities: A population-based study. Arch Intern Med 2006, 166:1649-1654.
4. Kato K, Sullivan PF, Evengard B, Pedersen NL: A population-based twin study of functional somatic syndromes. Psychol Med 2008, 39:497-505.
5. Mogil JN, Yu L, Basbaum AI: Pain genes?: natural variation and transgenic mutants. Annu Rev Neurosci 2000, 23: 777-811.
6. Diatchenko L, Slade GD, Nackley AG, et al.: Genetic basis for individual variations in pain perception and the development of a chronic pain condition. Hum Mol Genet 2005, 14:135-143.
7. Diatchenko L, Nackley AG, Slade GD, et al.: Catechol-O-methyltransferase gene polymorphisms are associated with multiple pain-evoking stimuli. Pain 2006, 125:216-224.
8. Buskila D, Cohen H, Neumann L, Ebstein RP: An association between fibromyalgia and the dopamine D4 receptor exon III repeat polymorphism and relationship to novelty seeking personality traits. Mol Psychiatry 2004, 9:730-731.
9. Arnold LM, Hess EV, Hudson JI, et al.: A randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia. Am J Med 2002, 112:191-197.
10. Wolfe F: The relation between tender points and fibromyalgia symptom variables: Evidence that fibromyalgia is not a discrete disorder in the clinic. Ann Rheum Dis 1997, 56:268-271.
11. Petzke F, Gracely RH, Park KM, et al.: What do tender points measure? Influence of distress on 4 measures of tenderness. J Rheumatol 2003, 30:567-574.
12. Petzke F, Clauw DJ, Ambrose K, et al.: Increased pain sensitivity in fibromyalgia: Effects of stimulus type and mode of presentation. Pain 2003, 105:403-413.
13. Kosek E, Hansson P: Modulatory influence on somatosensory perception from vibration and heterotopic noxious conditioning stimulation (HNCS) in fibromyalgia patients and healthy subjects. Pain 1997, 70:41-51.
14. Arroyo JF, Cohen ML: Abnormal responses to electrocutaneous stimulation in fibromyalgia. J Rheumatol 1993, 201:1925-1931.
15. Harris RE, Gracely RH, McLean SA, et al.: Comparison of clinical and evoked pain measures in fibromyalgia. J Pain 2006, 77:521-527.
16. Julien N, Goffaux P, Arsenault P, Marchand S: Widespread pain in fibromyalgia is related to a deficit of endogenous pain inhibition. Pain 2005, 114:295-302.
17. Wilder-Smith CH, Robert-Yap J: Abnormal endogenous pain modulation and somatic and visceral hypersensitivity in female patients with irritable bowel syndrome. World J Gastroenterol 2007, 13:3699-3704.
18. Maixner W, Fillingim R, Booker D, Sigurdsson A: Sensitivity of patients with painful temporomandibular disorders to experimentally evoked pain. Pain 1995, 63:341-351.
19. Baraniuk JN, Whalen G, Cunningham J, Clauw DJ: Cerebrospinal fluid levels of opioid peptides in fibromyalgia and chronic low back pain. BMC Musculoskelet Disord 2004, 5:48.
20. Price DD, Staud R, Robinson ME, et al.: Enhanced temporal summation of second pain and its central modulation in fibromyalgia patients. Pain 2002, 99:49-59.
21. Sarchielli P, Di FM, Nardi K, Calabresi P: Sensitization, glutamate, and the link between migraine and fibromyalgia. Curr Pain Headache Rep 2007, 11:343-351.
22. Guedj E, Cammilleri S, Niboyet J, et al.: Clinical correlate of brain SPECT perfusion abnormalities in fibromyalgia. J Nucl Med 2008, 1798-1803.
23. Adiguzel O, Kaptanoglu E, Turgut B, Nacitarhan V: The possible effect of clinical recovery on regional cerebral blood flow deficits in fibromyalgia: A prospective study with semiquantitative SPECT. South Med J 2004, 97:651-655.
24. Gracely RH, Petzke F, Wolf JM, Clauw DJ: Functional magnetic resonance imaging evidence of augmented pain processing in fibromyalgia. Arthritis Rheum 2002, 46:1333-1343.
25. Giesecke T, Gracely RH, Williams DA, et al.: The relationship between depression, clinical pain, and experimental pain in a chronic pain cohort. Arthritis Rheum 2005, 52:1577-1584.
26. Wood PB, Patterson JC, Sunderland JJ, et al.: Reduced presynaptic dopamine activity in fibromyalgia syndrome demonstrated with positron emission tomography: A pilot study. J Pain 2007, 8:51-58.
27. Harris RE, Clauw DJ, Scott DJ, et al.: Decreased central mu-opioid receptor availability in fibromyalgia. J Neurosci 2007, 27:10000-10006.
28. Harris RE, Sundgren PC, Pang Y, et al.: Dynamic levels of glutamate within the insula are associated with improvements in multiple pain domains in fibromyalgia. Arthritis Rheum 2008, 58:903-907.
29. Alanoglu E, Ulas UH, Ozdag F, et al.: Auditory event-related brain potentials in fibromyalgia syndrome. Rheumatol Int 2005, 25:345-349.
30. Branco J, Atalaia A, Paiva T: Sleep cycles and alpha-delta sleep in fibromyalgia syndrome. J Rheumatol 1994, 21:1113-1117.
31. Edinger JD, Wohlgemuth WK, Krystal AD, Rice JR: Behavioral insomnia therapy for fibromyalgia patients: A randomized clinical trial. Arch Intern Med 2005, 165:2527-2535.
32. Crofford LJ, Young EA, Engleberg NC, et al.: Basal circadian and pulsatile ACTH and cortisol secretion in patients with fibromyalgia and/ or chronic fatigue syndrome. Brain Behav Immun 2004, 18:314-325.
33. Ataoglu S, Ozcetin A, Yildiz O, Ataoglu A: Evaluation of dexamethasone suppression test in fibromyalgia patients with or without depression. Swiss Med Wkly 2003, 133:241-244.
34. Macedo JA, Hesse J, Turner JD, et al.: Glucocorticoid sensitivity in fibromyalgia patients: Decreased expression of corticosteroid receptors and glucocorticoid-induced leucine zipper. Psychoneuroendocrinology 2008, 33:799-809.
35. McBeth J, Silman AJ, Gupta A, et al.: Moderation of psychosocial risk factors through dysfunction of the hypothalamic-pituitary-adrenal stress axis in the onset of chronic widespread musculoskeletal pain: Findings of a population-based prospective cohort study. Arthritis Rheum 2007, 56:360-371.
36. McLean SA, Williams DA, Stein PK, et al.: Cerebrospinal fluid corticotropin-releasing factor concentration is associated with pain but not fatigue symptoms in patients with fibromyalgia. Neuropsychopharmacology 2006, 31:2776-2782.
37. Glass JM, Lyden A, Petzke F, Clauw D: The effect of brief exercise cessation on pain, fatigue, and mood symptom development in healthy, fit individuals. J Psychosom Res 2004, 57:391-398.
38. Yarnitsky D, Sprecher E, Zaslansky R, Hemli JA: Multiple session experimental pain measurement. Pain 1996, 67:327-333.
39. Sarchielli P, Di Filippo M, Nardi K, Calabresi P: Sensitization, glutamate, and the link between migraine and fibromyalgia. Curr Pain Headache Rep 2007, 11:343-351.
40. Harris RE, Clauw DJ: How do we know that the pain in fibromyalgia is "real"? Curr Pain Headache Rep 2006, 10:403-407.
41. Sarchielli P, Di Filippo M, Nardi K, Calabresi P: Sensitization, glutamate, and the link between migraine and fibromyalgia. Curr Pain Headache Rep 2007, 11:343-351.
42. Laske C, Stransky E, Eschweiler GW, et al.: Increased BDNF serum concentration in fibromyalgia with or without depression or antidepressants. J Psychiatr Res 2007, 41:600-605.
43. Okifuji A, Turk DC: Sex hormones and pain in regularly menstruating women with fibromyalgia syndrome. J Pain 2006, 71:851-859.
44. Gur A, Oktayoglu P: Status of immune mediators in fibromyalgia. Curr Pain Headache Rep 2008, 12:175-181.
45. Elenkov IJ, Papanicolaou DA, Wilder RL, Chrousos GP: Modulatory effects of glucocorticoids and catecholamines on human interleukin-12 and interleukin-10 production: Clinical implications. Proc Assoc Am Physicians 1996, 108:374-381.
46. Jalalvand E, Javan M, Haeri-Rohani A, Ahmadiani A: Stress- and non-stress-mediated mechanisms are involved in pain-induced apoptosis in hippocampus and dorsal lumbar spinal cord in rats. Neuroscience 2008, 157:446-452.
47. Kim SH, Kim DH, Oh DH, Clauw DJ: Characteristic electron microscopic findings in the skin of patients with fibromyalgia-preliminary study. Clin Rheumatol 2008, 27:407-411.